Seizert Capital Partners LLC Has $1.11 Million Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

Seizert Capital Partners LLC decreased its stake in QuidelOrtho Co. (NASDAQ:QDEL) by 1.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 24,242 shares of the company’s stock after selling 321 shares during the period. Seizert Capital Partners LLC’s holdings in QuidelOrtho were worth $1,105,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in QDEL. Capital Performance Advisors LLP acquired a new stake in QuidelOrtho during the third quarter worth approximately $25,000. Fifth Third Bancorp grew its stake in QuidelOrtho by 907.3% during the second quarter. Fifth Third Bancorp now owns 826 shares of the company’s stock worth $27,000 after purchasing an additional 744 shares during the period. GAMMA Investing LLC grew its stake in QuidelOrtho by 27.0% during the second quarter. GAMMA Investing LLC now owns 1,778 shares of the company’s stock worth $59,000 after purchasing an additional 378 shares during the period. EMC Capital Management acquired a new stake in QuidelOrtho during the first quarter worth approximately $117,000. Finally, Innealta Capital LLC acquired a new stake in QuidelOrtho during the second quarter worth approximately $102,000. Institutional investors and hedge funds own 99.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Craig Hallum raised QuidelOrtho from a “hold” rating to a “buy” rating and raised their target price for the stock from $40.00 to $57.00 in a research note on Thursday, September 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price target on shares of QuidelOrtho in a report on Friday, August 16th. Finally, UBS Group initiated coverage on QuidelOrtho in a report on Thursday, September 19th. They issued a “neutral” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $58.83.

QuidelOrtho Stock Down 7.1 %

Shares of NASDAQ:QDEL opened at $36.18 on Monday. QuidelOrtho Co. has a 52-week low of $29.74 and a 52-week high of $75.86. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.81 and a current ratio of 1.38. The business’s 50 day simple moving average is $42.03 and its two-hundred day simple moving average is $40.45. The firm has a market cap of $2.43 billion, a P/E ratio of -1.30 and a beta of 0.12.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Thursday, November 7th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.55. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. The company had revenue of $727.00 million for the quarter, compared to analyst estimates of $642.16 million. During the same quarter last year, the company earned $0.90 earnings per share. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. As a group, research analysts forecast that QuidelOrtho Co. will post 1.72 EPS for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.